February 1, 2022

Next Wave of Psychedelic Drug Development: Pain & Eating Disorders | TRYP Therapeutics $TRYP

Midas Letter
Midas Letter
Next Wave of Psychedelic Drug Development: Pain & Eating Disorders | TRYP Therapeutics $TRYP
/

TRYP Therapeutics Inc (CNSX:TRYP, OTCMKTS:TRYPF) is developing the next wave of psychedelic drugs. TRYP aims to commercialize psilocybin for unique therapeutic areas like chronic pain and eating disorders.

“We decided there are plenty of other companies working in depression, PTSD and anxiety. That’s terrific and we’re certainly rooting on the sidelines for those companies to be successful as well, but we believe the value that TRYP Therapeutics will bring is going to be around taking these chemistries that are known to be active and tolerated and point them towards these other patient populations that have a high unmet medical need” – TRYP Therapeutics CEO Greg McKee

TRYP has an exclusive supply of psilocybin-based active ingredients and drug products, with sufficient material to support its ongoing clinical trials. The company recently announced an upcoming Phase 2a clinical trials with the University of Michigan and Florida to evaluate its drug products for fibromyalgia and overeating disorders.

Beyond developing psilocybin-based compounds to treat diseases with unmet medical needs, TRYP Therapeutics is focused on creating a standard route of administration that will create a more constant patient experience with a better safety profile. Namely, the company’s TRP-8803 product uses a novel formulation for that improved delivery method.

Transcript

00:00 – TRYP Therapeutics $TRYP $TRYPF CEO Greg McKee
00:41 – Business overview
01:05 – Competition & TRYP Niche
02:24 – Psilocybin-derived compound & administration
04:30 – Psychotherapy protocols & psychotherapists
07:55 – Milestones timeline
09:44 – Regulatory landscape

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.